ES2140409T3 - Agente de contraste para rayos x. - Google Patents

Agente de contraste para rayos x.

Info

Publication number
ES2140409T3
ES2140409T3 ES92911840T ES92911840T ES2140409T3 ES 2140409 T3 ES2140409 T3 ES 2140409T3 ES 92911840 T ES92911840 T ES 92911840T ES 92911840 T ES92911840 T ES 92911840T ES 2140409 T3 ES2140409 T3 ES 2140409T3
Authority
ES
Spain
Prior art keywords
rays
contrast agent
compounds
molecula
phospholipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911840T
Other languages
English (en)
Inventor
Bengt Herslof
Kare Larsson
Stig Bengmark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2140409T3 publication Critical patent/ES2140409T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Tires In General (AREA)

Abstract

LA INVENCION SE REFIERE A UN COMPUESTO CON BASE DE FOSFOLIPIDOS, ESTO ES UN FOSFOLIPIDO AL CUAL SE ENCUENTRE COVALENTEMENTE UNIDA LA MOLECULA QUE DA CONTRASTE PARA LOS RAYOS X, A LOS LIPOSOMAS QUE COMPRENDEN DICHOS COMPUESTOS ASI COMO AL USO DE DICHOS LIPOSOMAS COMO AGENTES DE CONTRASTE Y DE DIAGNOSTICO.
ES92911840T 1991-06-03 1992-06-03 Agente de contraste para rayos x. Expired - Lifetime ES2140409T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101709A SE9101709L (sv) 1991-06-03 1991-06-03 Lipidderivat som diagnostikum eller kontrastmedel

Publications (1)

Publication Number Publication Date
ES2140409T3 true ES2140409T3 (es) 2000-03-01

Family

ID=20382938

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911840T Expired - Lifetime ES2140409T3 (es) 1991-06-03 1992-06-03 Agente de contraste para rayos x.

Country Status (13)

Country Link
US (1) US5550263A (es)
EP (1) EP0588869B1 (es)
JP (1) JP3013939B2 (es)
AT (1) ATE185490T1 (es)
AU (1) AU652260B2 (es)
CA (1) CA2103462C (es)
DE (1) DE69230144T2 (es)
DK (1) DK0588869T3 (es)
ES (1) ES2140409T3 (es)
FI (1) FI935386A0 (es)
NO (1) NO308126B1 (es)
SE (1) SE9101709L (es)
WO (1) WO1992021384A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE470086B (sv) * 1991-04-23 1993-11-08 Kabi Pharmacia Ab Organspecifik emulsion
US6217849B1 (en) * 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
CA2407654C (en) * 2000-04-28 2009-06-30 Fuji Photo Film Co., Ltd. Liposome containing hydrophobic iodine compound
ATE375173T1 (de) * 2001-08-20 2007-10-15 Fujifilm Corp Hydrophobe iodverbindung enthaltendes liposom und dieses enthaltendes röntgenkontrastmittel
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US7498018B2 (en) * 2003-10-03 2009-03-03 Bracco Diagnostics Inc. Contrast media for use in medical and diagnostic procedures and methods of using the same
DE102004049652A1 (de) * 2004-10-11 2006-04-20 Degussa Ag Leitungssystem für Fluide und Gase in einer Brennstoffzelle
WO2007129311A2 (en) * 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013121284A1 (en) * 2012-02-14 2013-08-22 Universite De Strasbourg Iodinated products intended for a use for the medical imaging and their methods of preparation
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
ES2897624T3 (es) * 2013-03-15 2022-03-02 Univ California Material de contraste entérico para TC basado en átomos de z baja
CN105848582A (zh) 2013-08-16 2016-08-10 加利福尼亚大学董事会 硅酮基肠道ct对比材料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235792A (en) * 1977-04-14 1980-11-25 The Governing Council Of The University Of Toronto Immunological materials
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
CH641682A5 (en) * 1978-10-05 1984-03-15 Daeniker Felix X-ray contrast medium
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
JPS59187792A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質糖類誘導体の製法
EP0262876B1 (en) * 1986-09-27 1992-04-29 Toyo Jozo Kabushiki Kaisha Nucleoside-phospholipid conjugate
JPS63233374A (ja) * 1987-03-20 1988-09-29 Tohoku Denshi Sangyo Kk 過酸化脂質の測定方法およびその測定装置
CH672733A5 (es) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
CA1340413C (en) * 1987-09-09 1999-03-02 Chiron Diagnostics Corporation Method of preparing phosphodiester conjugates useful for immunoactive liposomes

Also Published As

Publication number Publication date
FI935386L (fi) 1993-12-01
CA2103462A1 (en) 1992-12-04
NO934383D0 (no) 1993-12-02
ATE185490T1 (de) 1999-10-15
WO1992021384A1 (en) 1992-12-10
US5550263A (en) 1996-08-27
AU1903392A (en) 1993-01-08
JP3013939B2 (ja) 2000-02-28
SE9101709L (sv) 1992-12-04
DE69230144D1 (de) 1999-11-18
EP0588869B1 (en) 1999-10-13
NO934383L (no) 1993-12-02
SE9101709D0 (sv) 1991-06-03
NO308126B1 (no) 2000-07-31
DK0588869T3 (da) 2000-04-17
CA2103462C (en) 1998-03-31
FI935386A7 (fi) 1993-12-01
JPH06510276A (ja) 1994-11-17
DE69230144T2 (de) 2000-05-25
FI935386A0 (fi) 1993-12-01
EP0588869A1 (en) 1994-03-30
AU652260B2 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
ES2140409T3 (es) Agente de contraste para rayos x.
HN1998000157A (es) Agonistas de prostaglandinas
ES2052881T3 (es) Agentes reductores de la presion sanguinea.
ES2173978T3 (es) Utilizacion de un alcohol graso insaturado.
ES2196211T3 (es) Prepolimeros de poliuretano que presentan grupos alcoxisilano e hidantoina, un procedimiento para su preparacion asi como uso para la preparacion de materiales de sellado.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES2147310T3 (es) Material compuesto con contenido de aerogel, procedimiento para su elaboracion, asi como modo de aplicacion.
ES2178298T3 (es) Compuestos anti-inflamatorios.
ES2053510T3 (es) Analogos de rebecamicina.
ES2152998T3 (es) Agente anticomplementario obtenido a partir de fucanos de algas pardas.
AR004498A1 (es) Compuestos de aminofosfonato y composiciones farmaceuticas que los contienen, el uso de los mismos, y un procedimiento para su preparacion
ES2144151T3 (es) Benzotiazepinas hipolipidemicas.
ES2149378T3 (es) Procedimiento para la sulfonilacion, sulfenilacion y fosforilacion de depsipeptidos ciclicos.
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2126766T3 (es) 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo.
ES2115060T3 (es) Microparticulas, procedimiento para su produccion, asi como la utilizacion de estas para finalidades de diagnostico.
PA8452701A1 (es) Agonistas de prostaglandinas
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
CO4950531A1 (es) Analogos de la vitamina d3 composciiones farmaceuticas que los contienen
ES2119326T3 (es) Compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ES2177656T3 (es) Derivados de antraciclinona y su utilizacion en el tratamiento de la amiloidosis.
ES2120145T3 (es) Compuestos bi-aromaticos acetilenados con grupo adamantilo, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2104133T3 (es) Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 588869

Country of ref document: ES